Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $47

Benzinga Newsdesk www.benzinga.com Positive 62.3%

Neg 0% Neu 0% Pos 62.3%

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $37 to $47.